Back to portfolio
This program focuses on developing high affinity molecular traps derived from human neuropilin-1 in order to neutralize Semaphorin 3A, and to test their efficacy in animal models of retinal edema. This program, led by Dr. Mike (Przemyslaw) Sapieha from the Université de Montreal and Maisonneuve-Rosemont Hospital, has now been spun out into SemaThera; an AmorChem start-up company.